(MT Newswires) -- Dutch Philips Group (PHG) CEO Roy Jakobs discusses the consequences of the sleep apnea machine recall. The Dutch medical equipment manufacturer has not given a definitive figure for the cost of the recall, as the legal proceedings are not over, but claims that 99% of defective devices have been replaced. While the company has recorded three consecutive quarters of growth, it points to investments in artificial intelligence, estimated at over a billion euros a year.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.74 EUR | +2.49% | +4.75% | -6.36% |
Apr. 26 | ResMed tops quarterly profit estimates on strong demand for sleep apnea devices | RE |
Apr. 23 | PHILIPS NV : Jefferies reiterates its Sell rating | ZD |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.36% | 19.11B | |
+8.07% | 219B | |
+6.59% | 183B | |
+11.26% | 133B | |
+26.57% | 108B | |
+0.65% | 63.06B | |
+13.35% | 52.02B | |
-0.62% | 48.2B | |
-0.93% | 40.37B | |
+11.54% | 39.35B |
- Stock Market
- Equities
- PHIA Stock
- News Philips NV
- Product recalls, renewed growth, investment in AI. Roy Jakobs, Philips CEO